Table 1.
Some additional researches in the subject of growth factor-based targeted therapy in lung cancer (data consulted on 6 July 2023) [56,57].
| Last Update | Location and Study Identifier | Study Type | Study Title | Condition | Intervention | Status | Findings |
|---|---|---|---|---|---|---|---|
| May 2023 |
United Kingdom NCT04179890 |
Observational and retrospective | The study observes how long patients with non-small cell lung cancer (NSCLC) benefit from treatment with epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) when given either for uncommon mutations or for common mutations in the sequence afatinib followed by osimertinib (UpSwinG) | Non-squamous, Non-Small Cell Lung Cancer, | Observation of EGFR-TKI: -Afatinib -Erlotinib -Gefitinib -Osimertinib |
Complete | treatment with EGFR-TKI should be considered as standard for most patients with uncommon mutations |
| February 2023 |
USA NCT05062980 |
Clinical Trial | Quaratusugene Ozeplasmid (Reqorsa) in combination with Pembrolizumab in previously treated Non-Small Cell Lung Cancer (Acclaim-2) Phase I/II |
Non-Small Cell Lung Cancer | A: Quaratusugene ozeplasmid (pan-TKI: EGFR and Akt inhibitor) + Pembrolizumab (VEGFR downstream inhibitor: PD1 inhibitor) B: Docetaxel (microtubule inhibitor) + ramucirumab (VEGFR inhibitor) + 3rd molecule proposed by physician |
On going | / |
| May 2019 |
United Kingdom NCT02109016 |
Clinical Trial | A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, Lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. | Advance stage of Small and Non-small cell lung cancer with adenomatous, squamous, and large cell histologies, as well as FGF, VEGF, or PDGF genetic alterations. |
Lucitanib, a VEGFR-FGFR tyrosine kinase inhibitor | Terminated | Interim analysis was either impossible (due to short time data collection) or showed low probability of clinically significant result |
| January 2013 |
USA NCT00862134 |
Clinical Trial | Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) Phase II |
Non-Small Cell Lung Cancer | A: Docetaxel (microtubule inhibitor) B: Docetaxel + PR104 (hypoxia-activated prodrug) + G-CSF for prophylaxis |
Terminated | Interim analysis indicated low probability of clinically significant result |